Is Fate Therapeutics Inc (FATE) overvalued? · rev $13.6M
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
This page asks whether Fate Therapeutics Inc (FATE) looks expensive on cached numbers — not a short thesis.
Latest reported FATE revenue for 2024-12-31 was $13.6M. Net income was -$186.3M. Revenue was down 78.5% from 2023-12-31 to 2024-12-31. FATE currently screens at market cap $331.0M.
FATE currently screens at market cap $331.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next FATE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the FATE stock page for the full model, not this heading.
Not investment advice.